The Global Heparin Market Is Witnessing High Growth

 

Heparin, also known as unfractionated heparin (UFH), is a glycosaminoglycan that occurs naturally. In medicine, it is used as an anticoagulant (blood thinner). It is especially useful in the treatment of heart attacks and unstable angina. It is injected into a vein or under the skin. It is used to treat a variety of medical conditions, including acute coronary syndrome, deep vein thrombosis, pulmonary embolism, and atrial fibrillation, as well as cardiopulmonary bypass and hemofiltration during cardiac surgery. It is also used in the administration of major orthopedic procedures such as hip and knee replacements.

Heparin Market  is regarded as one of the most important life-saving drugs available in the world today. It can be used to manage and treat a wide range of chronic diseases. This product is an anticoagulant, which is used to treat a variety of cardiovascular diseases such as deep vein thrombosis and pulmonary embolism. However, the Heparin Market suffers from unfavorable factors such as product contamination, which resulted in several deaths in 2007-2008, and issues related to supply chain disruption. Despite this, the drug's critical nature has led to its continued existence by several major companies such as Baxter and Pfizer, assisting global heparin market growth during the forecast period.

Because the drug is considered a life-saving medication for chronic disorders, the COVID-19 pandemic has had little impact on the global market. At the same time, the accumulation of specific types of the product, as well as its use as a COVID-19 therapeutic, has increased demand for specific treatment procedures. However, in the early days of the pandemic, some instances of the pandemic causing impediments on the global Heparin Market  included a sharp decrease in hospital visits worldwide and supply issues because the raw material is sourced from China. The global market, however, has recovered well from the pandemic's initial negative impact.

Key Players

Anselm Pharmaceuticals, Baxter International Inc., B. Braun Melsungen AG, Bristol-Myers Squibb Co., Dr. Reddy's Laboratories Ltd., Fresenius SE & Co. KGaA, Leap Labchem Co., LEO Pharma A/S, Pfizer, Inc., Sanofi S.A., Syntex S.A., Teva Pharmaceutical Industries Ltd., and United Biotech (P) Ltd.